139 related articles for article (PubMed ID: 17694395)
1. In situ-forming oleogel implant for rivastigmine delivery.
Vintiloiu A; Lafleur M; Bastiat G; Leroux JC
Pharm Res; 2008 Apr; 25(4):845-52. PubMed ID: 17694395
[TBL] [Abstract][Full Text] [Related]
2. Preparation and evaluation of injectable sustained-release microspheres of rivastigmine.
Zhu Y; Zhu Z; Cao Q; Chen D; Cui J
J Control Release; 2011 Nov; 152 Suppl 1():e131-2. PubMed ID: 22195801
[No Abstract] [Full Text] [Related]
3. Tyrosine-based rivastigmine-loaded organogels in the treatment of Alzheimer's disease.
Bastiat G; Plourde F; Motulsky A; Furtos A; Dumont Y; Quirion R; Fuhrmann G; Leroux JC
Biomaterials; 2010 Aug; 31(23):6031-8. PubMed ID: 20472283
[TBL] [Abstract][Full Text] [Related]
4. A study of rivastigmine liposomes for delivery into the brain through intranasal route.
Arumugam K; Subramanian GS; Mallayasamy SR; Averineni RK; Reddy MS; Udupa N
Acta Pharm; 2008 Sep; 58(3):287-97. PubMed ID: 19103565
[TBL] [Abstract][Full Text] [Related]
5. Enhanced brain distribution and pharmacodynamics of rivastigmine by liposomes following intranasal administration.
Yang ZZ; Zhang YQ; Wang ZZ; Wu K; Lou JN; Qi XR
Int J Pharm; 2013 Aug; 452(1-2):344-54. PubMed ID: 23680731
[TBL] [Abstract][Full Text] [Related]
6. New perspective for the treatment of Alzheimer diseases: liposomal rivastigmine formulations.
Mutlu NB; Değim Z; Yilmaz Ş; Eşsiz D; Nacar A
Drug Dev Ind Pharm; 2011 Jul; 37(7):775-89. PubMed ID: 21231901
[TBL] [Abstract][Full Text] [Related]
7. Development of a novel dry powder inhalation formulation for the delivery of rivastigmine hydrogen tartrate.
Simon A; Amaro MI; Cabral LM; Healy AM; de Sousa VP
Int J Pharm; 2016 Mar; 501(1-2):124-38. PubMed ID: 26836711
[TBL] [Abstract][Full Text] [Related]
8. [Preparation of rivastigmine liposome and its pharmacokinetics in rats after intranasal administration].
Yang ZZ; Wang ZZ; Wu K; Qi XR
Yao Xue Xue Bao; 2011 Jul; 46(7):859-63. PubMed ID: 22010358
[TBL] [Abstract][Full Text] [Related]
9. Development, characterization and application of in situ gel systems for intranasal delivery of tacrine.
Qian S; Wong YC; Zuo Z
Int J Pharm; 2014 Jul; 468(1-2):272-82. PubMed ID: 24709220
[TBL] [Abstract][Full Text] [Related]
10. In situ forming implant for controlled delivery of an anti-HIV fusion inhibitor.
Kapoor DN; Katare OP; Dhawan S
Int J Pharm; 2012 Apr; 426(1-2):132-143. PubMed ID: 22266533
[TBL] [Abstract][Full Text] [Related]
11. Preparation and characterization of rivastigmine loaded human serum albumin (HSA) nanoparticles.
Avachat AM; Oswal YM; Gujar KN; Shah RD
Curr Drug Deliv; 2014; 11(3):359-70. PubMed ID: 24893995
[TBL] [Abstract][Full Text] [Related]
12. Self-assembled L-alanine derivative organogel as in situ drug delivery implant: characterization, biodegradability, and biocompatibility.
Wang K; Jia Q; Han F; Liu H; Li S
Drug Dev Ind Pharm; 2010 Dec; 36(12):1511-21. PubMed ID: 21050137
[TBL] [Abstract][Full Text] [Related]
13. Buccoadhesive films for once-a-day administration of rivastigmine: systematic formulation development and pharmacokinetic evaluation.
Kapil R; Dhawan S; Beg S; Singh B
Drug Dev Ind Pharm; 2013 Mar; 39(3):466-80. PubMed ID: 22409834
[TBL] [Abstract][Full Text] [Related]
14. Bioequivalence evaluation of two brands of rivastigmine of different salt forms, an acetylcholinesterase inhibitor for the treatment of Alzheimer's disease, in healthy Beagle dogs.
Shen C; Yang B; Zhou T; Duan G; Yu Y
Pharmazie; 2011 Aug; 66(8):590-3. PubMed ID: 21901981
[TBL] [Abstract][Full Text] [Related]
15. Investigation of liposome formulation effects on rivastigmine transport through human colonic adenocarcinoma cell line (CACO-2).
Degim Z; Mutlu NB; Yilmaz S; Eşsiz D; Nacar A
Pharmazie; 2010 Jan; 65(1):32-40. PubMed ID: 20187576
[TBL] [Abstract][Full Text] [Related]
16. Rivastigmine in Parkinson's disease dementia.
Lalli S; Albanese A
Expert Rev Neurother; 2008 Aug; 8(8):1181-8. PubMed ID: 18671661
[TBL] [Abstract][Full Text] [Related]
17. In Vitro and in Vivo Optimization of Phase Sensitive Smart Polymer for Controlled Delivery of Rivastigmine for Treatment of Alzheimer's Disease.
Lipp L; Sharma D; Banerjee A; Singh J
Pharm Res; 2020 Jan; 37(3):34. PubMed ID: 31942651
[TBL] [Abstract][Full Text] [Related]
18. Formulation and characterization of injectable poly(DL-lactide-co-glycolide) implants loaded with N-acetylcysteine, a MMP inhibitor.
Desai KG; Mallery SR; Schwendeman SP
Pharm Res; 2008 Mar; 25(3):586-97. PubMed ID: 17891553
[TBL] [Abstract][Full Text] [Related]
19. Rivastigmine transdermal patch: role in the management of Alzheimer's disease.
Guay DR
Consult Pharm; 2008 Aug; 23(8):598-609. PubMed ID: 19032006
[TBL] [Abstract][Full Text] [Related]
20. Development and evaluation of rivastigmine loaded chitosan nanoparticles for brain targeting.
Fazil M; Md S; Haque S; Kumar M; Baboota S; Sahni JK; Ali J
Eur J Pharm Sci; 2012 Aug; 47(1):6-15. PubMed ID: 22561106
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
